Impact of iv Dexamethasone on Reversal of Rocuronium-induced Neuromuscular Block by Sugammadex

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02562417

Enrollment

Registered

2015-09-29

Start date

2016-06-30

Completion date

2018-05-31

Last updated

2017-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromuscular Blockade

Brief summary

Sugammadex is used as a reversal drug for rocuronium- or vecuronium-induced neuromuscular block during general anaesthesia. IV dexamethasone is injected as a prophylactic measure against postoperative nausea and vomiting. Recent animal data have shown that dexamethasone may impair the reversal effect of sugammadex. The objective of this randomised controlled trial is to confirm in the clinical practice these preliminary results.

Interventions

DRUGNormal saline

DRUGIV dexamethasone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients scheduled to undergo microlaryngoscopy and ear-nose-throat endoscopic procedures

Exclusion criteria

* contraindication to dexamethasone administration * contraindication to sugammadex administration * contraindication to rocuronium administration

Design outcomes

Primary

Measure	Time frame
Mean recovery time for T4/T1 ratio > 90% after sugammadex administration	surgical procedure

Secondary

Measure	Time frame
Mean recovery time for T4/T1 ratio > 70% after sugammadex administration	surgical procedure
Mean recovery time for T4/T1 ratio > 80% after sugammadex administration	surgical procedure

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026